Expanding Product Portfolio into the Global Bone Disease Market
Celltrion announced on December 22 that it has recently launched the bone disease treatment "Stovoclo-Osenbelt" (active ingredient: denosumab) in major European countries, including Germany, Spain, and France.
Celltrion plans to actively carry out promotional activities targeting healthcare professionals and patients in Germany following the launch of Stovoclo-Osenbelt. It is estimated that there are about 6 million potential osteoporosis patients in Germany. Celltrion's German subsidiary, which recently launched the ophthalmic treatment "Eydenzelt" (active ingredient: aflibercept), intends to leverage the sales performance of its existing products to focus its marketing capabilities on the early market entry of new products.
In France, Celltrion will utilize its hospital-centered sales network, established through the sales of existing autoimmune disease treatments, to expand prescriptions of Stovoclo-Osenbelt. In particular, the local subsidiary's sales team believes that a significant number of rheumatologists and other specialists in autoimmune diseases-previously the main target for sales-could become potential prescribers of Stovoclo. The company plans to intensify its promotional activities to accelerate its market penetration.
Additionally, in Spain, where Celltrion began direct sales in May this year, the launch of Stovoclo-Osenbelt has been completed. Celltrion will supply the intravenous (IV) formulation, Osenbelt, through its local subsidiary, which has a strong presence in hospital channels, while the subcutaneous (SC) formulation, Stovoclo, will be supplied through distribution partners with high competitiveness in the retail (sales) channel.
Celltrion plans to gradually expand the number of European countries where Stovoclo-Osenbelt is available, thereby strengthening its position in the bone disease treatment market. With the demand for bone disease treatments steadily increasing due to the aging population, the company aims to achieve early market leadership by leveraging its recognized strengths in supply stability and product competitiveness.
A Celltrion representative stated, "By launching Stovoclo-Osenbelt, we will provide high-quality biopharmaceuticals to European bone disease patients at reasonable prices, thereby improving treatment accessibility. At the same time, we can help reduce healthcare expenditures for governments, making this the optimal choice for both patients and healthcare systems. With a more diversified product portfolio, we will secure sustainable growth engines and further strengthen the competitiveness of our biosimilar business across Europe."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
